Immunocore obtains FDA blessing for Kimmtrak
Kimmtrak is the first TCR therapeutic, the first bispecific T cell engager to treat a solid tumor and the first and only therapy for the treatment of unresectable or metastatic uveal melanoma to be approved by the FDA.